2nd Quarter - Report

INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH for INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH

Firm
Client
Income
—
Expenses
$40,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Funding for biomedical research.

LobbyistCovered position, as disclosed
ERIC D ANTHONY —
MEGAN DONOVAN New —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); SENATE

Health Issues HCR

- Regulation of stem cell-based products as biologics. - The use of fetal tissue and chimeras in biomedical research.

LobbyistCovered position, as disclosed
ERIC D ANTHONY —
MEGAN DONOVAN New —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Natl Institutes of Health (NIH)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.